Mylan’s CEO A Villain? Depends On Your Preferred Brand Of Capitalism

http://healthaffairs.org/blog/2016/09/06/mylans-ceo-a-villain-depends-on-your-preferred-brand-of-capitalism/

Image result for capitalism

Different Flavors Of Capitalism

As usual, the answer is a clear “No” and “Yes,” and resolving the question raises much deeper issues than one executive’s personal culpability. The answer depends on what definition of capitalism one deems appropriate. As the European economist André Sapir has noted, there are actually four distinct brands of capitalism in the Western economy, of which the version practiced in the United States and some other Anglo-Saxon countries—sometimes also referred to as “savage capitalism”—is but one.

The clearest version of raw Anglo Saxon capitalism, and one quoted widely to this day, was offered by the late Nobel Laureate economist Milton Friedman in his classic book “Capitalism and Freedom.” There he proposed that the one and only social obligation to society that the CEO of an investor-owned, for-profit company is “to maximize its profits while engaging in ‘open and free competition without deception and fraud.’” (Quoted in Thomas Carson’s “Friedman’s Theory of Corporate Social Responsibility.”) On that view, any corporate action that is legal is ipso facto ethical.

Ms. Bresch can argue that with her aggressive pricing policy on EpiPen she was merely owning up to this doctrine of Anglo-Saxon capitalism. Her board of directors may or may not have known about that policy with regard to this particular product, one of many the company sells. Here Ms. Bresch also can point out that she is in good company in the drug industry. Many drug companies beyond the poster-boys for what is now decried as “price gouging”—Valeant Pharmaceuticals International and Turing Pharmaceuticals—have adopted raw Anglo-Saxon capitalism as the intellectual foundation for their pricing policies by steadily raising prices on long existing drugs, year after year, or even quarter after quarter.

Malcolm Gladwell on Fixing the US Healthcare Mess

http://www.medscape.com/viewarticle/847495#vp_1

Image result for Malcolm Gladwell on Fixing the US Healthcare Mess

In this edition of One-on-One, Medscape Editor-in-Chief Eric J. Topol, MD, sits down with best-selling author and journalist Malcolm Gladwell, who shares his unique perspective on healthcare and the practice of medicine. Mr. Gladwell believes that reform in healthcare might begin if, at its most basic level, the practice functions as a cash economy. He also notes the frustration clinicians feel after being saddled with technology that has become more of a hindrance than a help, and believes that ultimately providers need to be allowed more time to spend with patients, and fewer mandates, if healthcare is to prosper.

Is There a Cure for High Drug Prices?

http://www.consumerreports.org/drugs/cure-for-high-drug-prices/

Image result for high drug costs

The cost of prescription drugs for tens of millions of Americans rose $2 billion last year, and all signs point to a continued rise. At stake is nothing less than the ability of Americans to afford the medicines they need. Can we stop the madness?

5 Reasons Prescription Drug Prices Are So High in the U.S.

http://finance.yahoo.com/news/5-reasons-prescription-drug-prices-172518972.html

Blame it on “government-protected” monopolies.
More

The “most important factor” that drives prescription drug prices higher in the United States than anywhere else in the world is the existence of government-protected “monopoly” rights for drug manufacturers, researchers at Harvard Medical School report today.

The researchers reviewed thousands of studies published from January 2005 through July 2016 in an attempt to simplify and explain what has caused America’s drug price crisis and how to solve it. They found that the problem has deep and complicated roots and published their findings in JAMA, the journal of the American Medical Association. The study was funded by the Laura and John Arnold Foundation with additional support provided by the Engelberg Foundation.

“I continue to be impressed at what a complex and nuanced problem it is and how there are no easy solutions either,” said lead study author Dr. Aaron Kesselheim, a professor who runs the Program on Regulation, Therapeutics and Law at Harvard Medical School and Brigham and Women’s Hospital. “As I was writing, the enormity of the problem continued to shine through.”

Five key findings in the JAMA review:

Showdown Looming on High Drug Prices?

http://www.medpagetoday.com/PublicHealthPolicy/HealthPolicy/59898?xid=fb_o_

Image result for high drug costs

Government intervention helped fuel the steep rise in prescription drug costs by granting monopolies to drug manufacturers and by mandating coverage in government-funded healthcare programs, authors of a review concluded.
In the U.S., per-capita spending on prescription drugs reached $858 in 2013, more than double the average for 19 other industrialized nations. Prescription spending accounted for 17% of the total cost of personal healthcare services.

The cost and complexity of drug development have contributed to the higher prices. However, the federal government essentially blocked the two most effective means of controlling prescription costs by delaying access to generics and placing constraints on government agencies’ ability to negotiate prices with drug manufacturers, Aaron S. Kesselheim, MD, JD, of Brigham and Women’s Hospital and Harvard Medical School, and co-authors wrote in the Aug. 23/30 issue of the Journal of the American Medical Association.

A timeline of eye-popping drug prices

http://www.usatoday.com/story/news/2016/08/25/timeline-eye-popping-drug-prices/89335852/

Image result for epipen

The firestorm over steep price increases for the EpiPen — which can rescue people having life-threatening allergic reactions  — is just the latest in a long line of controversies over high prescription drug prices. A decade ago, much of the concern over prescription drug prices involved new high-tech cancer drugs, used by only a few thousand patients a year. In recent years, the prices for decades-old generic drugs have soared, as well, as pharmaceutical companies purchase the rights for drugs with no competition.

Here’s a recap of some of the most eye-popping prices.

Pfizer’s Involvement in EpiPens Could Complicate Drug Price Debate

https://morningconsult.com/2016/08/26/pfizers-involvement-in-epipens-could-complicate-drug-price-debate/

cnythzl/iStock.com

Mylan Pharmaceuticals has come under intense fire for massive price hikes of EpiPens over the last week, facing scrutiny from lawmakers and industry groups. It is less well known, however, that while Mylan markets and prices the drug, Pfizer Inc. actually manufactures the drug and has seen increased revenues from EpiPens over the last few years.

The financial relationship between the two drug companies is unclear, and Pfizer declined to elaborate. Mylan did not respond to a request for further comment about EpiPens or how the two companies divide revenues.

“Meridian Medical Technologies is the contract manufacturer of EpiPen and takes great pride being able to supply a high quality and life-saving product. The terms of our supply agreement are confidential,” said Rachel Hooper, a Pfizer spokeswoman. Meridian Medical Technologies is a Pfizer subsidiary.

The EpiPen outrage centers around a 400 percent hike for the dispenser, used for emergency allergic reactions, since 2009, even though the product remains unchanged. It now costs as much as $600 for a pack of two EpiPens, which must be replaced every 12 to 18 months.